Free Trial

Q2 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

Vor Biopharma logo with Medical background

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of Vor Biopharma in a note issued to investors on Monday, June 30th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.25) per share for the quarter, down from their previous estimate of ($0.18). HC Wainwright has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.24 EPS.

VOR has been the topic of a number of other research reports. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. JMP Securities restated a "market perform" rating and issued a $6.00 price target on shares of Vor Biopharma in a research report on Friday, May 9th. Oppenheimer restated an "outperform" rating and issued a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, Citizens Jmp lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $5.63.

Check Out Our Latest Report on Vor Biopharma

Vor Biopharma Price Performance

Shares of NYSE VOR traded up $0.44 during mid-day trading on Wednesday, reaching $1.89. 24,491,873 shares of the company traded hands, compared to its average volume of 4,248,899. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $2.04. The firm has a market cap of $235.55 million, a PE ratio of -1.14 and a beta of 2.04. The stock has a fifty day simple moving average of $0.45 and a 200-day simple moving average of $0.85.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Vor Biopharma during the 4th quarter worth approximately $33,000. Money Concepts Capital Corp grew its position in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. Virtu Financial LLC purchased a new position in Vor Biopharma during the 4th quarter worth approximately $60,000. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the 4th quarter valued at $80,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

(Get Free Report)

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

Further Reading

Earnings History and Estimates for Vor Biopharma (NYSE:VOR)

Should You Invest $1,000 in Vor Biopharma Right Now?

Before you consider Vor Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.

While Vor Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines